{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:54Z","timestamp":1787009454743,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weight loss and exocrine pancreatic insufficiency are common in advanced pancreatic ductal adenocarcinoma (PDAC) and are associated with adverse outcomes. However, there is limited evidence on the impact of pancreatic enzyme replacement therapy (PERT) in patients with advanced PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively studied 501 patients with advanced PDAC and exocrine pancreatic insufficiency from the Virginia Mason Pancreas Cancer Program Data Resource treated between 2010 and 2019 with first-line chemotherapy. Clinical outcomes were compared between those who received PERT and those who did not at 8 weeks after chemotherapy start.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 188 (38%) patients received PERT; 313 patients (62%) did not. PERT patients experienced less weight loss (\u20131.5 vs \u20132.5 kg, P\u2005=\u2005.04), less decline in the prognostic nutrition index \u22121.9 vs \u22123.0, P\u2005=\u2005.01), and a greater reduction in the additive score of the Patient-Generated Subjective Global Assessment (\u20138.4 vs \u2013-6.0, P\u2005=\u2005.02). Importantly, median (95% CI) overall survival (OS) was significantly longer in the PERT vs non-PERT group (17.1 months vs 12.5 months, respectively P\u2005=\u2005.001), and the adjusted hazards ratio indicated superior median OS in patients prescribed PERT (HR\u2005=\u20050.73, P\u2005&amp;lt;\u2005.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that treatment of exocrine pancreatic insufficiency (EPI) in advanced PDAC is associated with improvements in nutrition and overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf014","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T15:11:15Z","timestamp":1737299475000},"source":"Crossref","is-referenced-by-count":5,"title":["Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3493-7769","authenticated-orcid":false,"given":"Vincent J","family":"Picozzi","sequence":"first","affiliation":[{"name":"Virginia Mason Hospital and Medical Center , Seattle, WA 98111 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret T","family":"Mandelson","sequence":"additional","affiliation":[{"name":"Benaroya Research Institute , Seattle, WA 98101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Najjar","sequence":"additional","affiliation":[{"name":"Benaroya Research Institute , Seattle, WA 98101 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moming","family":"Li","sequence":"additional","affiliation":[{"name":"Data and Statistical Sciences, AbbVie Inc. , North Chicago, IL 60064 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala E","family":"Harb","sequence":"additional","affiliation":[{"name":"US Medical Affairs, AbbVie Inc. , Mettawa, IL 60045 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J","family":"Kort","sequence":"additional","affiliation":[{"name":"US Medical Affairs, AbbVie Inc. , Mettawa, IL 60045 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025041509562961500_CIT0001","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025041509562961500_CIT0002","author":"Ferlay","year":"2024"},{"key":"2025041509562961500_CIT0003","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"2025041509562961500_CIT0004","volume-title":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet].","year":"2023  19"},{"key":"2025041509562961500_CIT0005","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2025041509562961500_CIT0006","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2025041509562961500_CIT0007","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2025041509562961500_CIT0008","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2025041509562961500_CIT0009","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"2025041509562961500_CIT0010","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025041509562961500_CIT0011","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-012-1514-8","article-title":"Symptoms in advanced pancreatic cancer are of importance for energy intake","volume":"21","author":"Bye","year":"2013","journal-title":"Support Care Cancer"},{"key":"2025041509562961500_CIT0012","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1111\/ajco.13669","article-title":"Loss of adipose tissue or skeletal muscle during first-line gemcitabine\/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer","volume":"18","author":"Miki","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025041509562961500_CIT0013","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1158\/1055-9965.EPI-19-0370","article-title":"Postdiagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer","volume":"28","author":"Babic","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025041509562961500_CIT0014","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12885-020-07753-w","article-title":"Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"2025041509562961500_CIT0015","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1634\/theoncologist.2018-0266","article-title":"Pancreas cancer-associated weight loss","volume":"24","author":"Hendifar","year":"2019","journal-title":"Oncologist"},{"key":"2025041509562961500_CIT0016","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.dld.2015.06.015","article-title":"Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature","volume":"47","author":"Bartel","year":"2015","journal-title":"Dig Liver Dis"},{"key":"2025041509562961500_CIT0017","first-page":"393","article-title":"Pancreatic enzyme supplementation in pancreatic cancer","volume":"6","author":"Damerla","year":"2008","journal-title":"J Support Oncol"},{"key":"2025041509562961500_CIT0018","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025041509562961500_CIT0019","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","journal-title":"Am J Surg"},{"key":"2025041509562961500_CIT0020","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.ejcn.1601412","article-title":"Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer","volume":"56","author":"Bauer","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"2025041509562961500_CIT0021","volume-title":"R: A Language and Environment for Statistical Computing [computer program]","year":"2023"},{"key":"2025041509562961500_CIT0022","author":"Common Terminology for Adverse Events (CTCAE) v5.0"},{"key":"2025041509562961500_CIT0023","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"2025041509562961500_CIT0024","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12885-018-4439-x","article-title":"Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis","volume":"18","author":"Dominguez-Munoz","year":"2018","journal-title":"BMC Cancer"},{"key":"2025041509562961500_CIT0025","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MPA.0000000000000767","article-title":"The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: a prospective cohort study","volume":"46","author":"Saito","year":"2017","journal-title":"Pancreas"},{"key":"2025041509562961500_CIT0026","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00520-017-3602-2","article-title":"Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC)","volume":"25","author":"Zdenkowski","year":"2017","journal-title":"Support Care Cancer"},{"key":"2025041509562961500_CIT0027","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1093\/oncolo\/oyad101","article-title":"Pancreatic enzyme replacement and nutritional support with n ab-paclitaxel-based first-line chemotherapy regimens in metastatic pancreatic cancer","volume":"28","author":"Giordano","year":"2023","journal-title":"Oncologist"},{"key":"2025041509562961500_CIT0028","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.clnu.2024.06.037","article-title":"Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanced pancreatic cancer and exocrine pancreatic insufficiency","volume":"43","author":"Klassen","year":"2024","journal-title":"Clin Nutr"},{"key":"2025041509562961500_CIT0029","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jcsm.12675","article-title":"The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers","volume":"12","author":"Wakabayashi","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025041509562961500_CIT0030","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/nejmoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"key":"2025041509562961500_CIT0031","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1021\/acs.jmedchem.2c02012","article-title":"Discovery of the potent and selective MC4R Antagonist PF-07258669 for the potential treatment of appetite loss","volume":"66","author":"Garnsey","year":"2023","journal-title":"J Med Chem"},{"key":"2025041509562961500_CIT0032","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025041509562961500_CIT0033","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pharmthera.2018.12.001","article-title":"New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids","volume":"196","author":"Gorjao","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025041509562961500_CIT0034","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2015.11.019","article-title":"Effects of immunonutrition for cystectomy on immune response and infection rates: a pilot randomized controlled clinical trial","volume":"69","author":"Hamilton-Reeves","year":"2016","journal-title":"Eur Urol"},{"key":"2025041509562961500_CIT0035","doi-asserted-by":"publisher","first-page":"e389942","DOI":"10.1200\/EDBK_389942","article-title":"Current therapeutic targets in cancer cachexia: a pathophysiologic approach","volume":"43","author":"Kadakia","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025041509562961500_CIT0036","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/ijms21041242","article-title":"Cisplatin-induced skeletal muscle dysfunction: mechanisms and counteracting therapeutic strategies","volume":"21","author":"Conte","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025041509562961500_CIT0037","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.21873\/anticanres.14210","article-title":"Skeletal muscle mass change during chemotherapy: a systematic review and meta-analysis","volume":"40","author":"Jang","year":"2020","journal-title":"Anticancer Res"},{"key":"2025041509562961500_CIT0038","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jcsm.12351","article-title":"Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer","volume":"10","author":"Naito","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025041509562961500_CIT0039","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/bmjspcare-2017-001440","article-title":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","volume":"8","author":"Solheim","year":"2018","journal-title":"BMJ Support Palliat Care"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf014\/62929097\/oyaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf014\/62929097\/oyaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:56:38Z","timestamp":1744696598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf014\/8113510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf014","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"oyaf014"}}